Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172028 · ClinicalTrials.gov registry record · Phase 1
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01172028 is a Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 33 participants.
The verdict
NCT01172028, a Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of giving pemetrexed disodium and docetaxel together in treating patients with advanced solid tumors.
Interventions
- DRUG Taxotere (Docetaxel)
- DRUG Alimta (Pemetrexed)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-09 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172028
The ClinicalTrials.gov registry entry for NCT01172028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Taxotere (Docetaxel) is the first listed.
NCT01172028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01172028 about?
NCT01172028 is a clinical study titled "Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: ...
What is the current status of trial NCT01172028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-09. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01172028?
The interventions under investigation include: Taxotere (Docetaxel) (DRUG), Alimta (Pemetrexed) (DRUG).
Who is sponsoring clinical trial NCT01172028?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.